BlackRock Health Sciences Term Trust
Last updated September 27, 2026
Organization details
- Legal name
- BlackRock Health Sciences Term Trust
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- BMEZ
- Primary stock exchange
- NYSE
Identifiers
- SEC CIK
- 0001785971
Board of directors
- Since 2023
-
Robert W. Fairbairn · DirectorSince 2025
Board connections
2 of this board's directors also sit on 35 other boards.
- via Arthur Philip Steinmetz and Robert W. Fairbairn
- via Arthur Philip Steinmetz and Robert W. Fairbairn
- via Arthur Philip Steinmetz and Robert W. Fairbairn
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
- via Arthur Philip Steinmetz
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $308,421
- 4 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 30, 2026 | Liu Xiang Portfolio Manager | Option exercise | +778 | — | — |
| Jan 30, 2026 | Xie H Erin Portfolio Manager | Option exercise | +25,676 | — | — |
| Jan 30, 2026 | Liu Xiang Portfolio Manager | Sold back to the company | −778 | $15.21 | $11,832 |
| Jan 30, 2026 | Xie H Erin Portfolio Manager | Sold back to the company | −25,676 | $15.21 | $390,536 |
| Dec 19, 2025 | Robert W. Fairbairn Director | Open-market sale | −0 | $14.96 | $6 |
| Dec 19, 2025 | Robert W. Fairbairn Director | Open-market sale | −0 | $14.96 | $6 |
| Dec 18, 2025 | Robert W. Fairbairn Director | Open-market sale | −10,294 | $14.98 | $154,204 |
| Dec 18, 2025 | Robert W. Fairbairn Director | Open-market sale | −10,294 | $14.98 | $154,204 |
| Apr 21, 2025 | Weinstein Boaz 10% owner | Change of control | −20,750,913 | $14.21 | $294,870,474 |
| Jan 31, 2025 | Xie H Erin Portfolio Manager | Option exercise | +14,883 | — | — |
| Jan 31, 2025 | McClements Kyle Portfolio Manager | Option exercise | +609 | — | — |
| Jan 31, 2025 | Accettella Christopher Portfolio Manager | Option exercise | +168 | — | — |
| Jan 31, 2025 | Liu Xiang Portfolio Manager | Option exercise | +225 | — | — |
| Jan 31, 2025 | Xie H Erin Portfolio Manager | Sold back to the company | −14,883 | $16.49 | $245,414 |
| Jan 31, 2025 | McClements Kyle Portfolio Manager | Sold back to the company | −609 | $16.49 | $10,046 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.